Protalix BioTherapeutics, Inc. has completed a private stock placement
Protalix BioTherapeutics, Inc. has raised funds to refinance the company for further development.
Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received the approval of the US Food and Drug Administration, for the treatment of Gaucher disease.
Oaklins’ team in Israel advised Protalix BioTherapeutics, Inc. and acted as a member in the distributors’ consortium.
Talk to the deal team
Related deals
AMC Media Group has been acquired by Formedics
AMC Media Group, a healthcare professional (HCP) community platform that enables medical associations and key opinion leaders (KOLs) to drive engagement and monetization through their specialty digital properties, has been acquired by Formedics, an HCP community and engagement platform that is home to Physician’s Weekly and OncWeekly.
Learn moreBellefleur has been acquired by Domidep
Belgian nursing home Bellefleur has been sold to Domidep, one of France’s largest private nursing home operators.
Learn moreManagement and founders of Sansidor have successfully invested alongside IK Partners
IK Partners has signed an agreement to invest in Sansidor, a fast-growing testing, inspection and related services provider. IK is investing in the group alongside existing shareholders HC Partners, founders of Sansidor’s group companies and the current management team.
Learn more